Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, it's from China. An experimental weekly injection developed by Chinese drugmaker Hengrui Pharma and its U.S.-based partner, Kailera Therapeutics, succeeded in a late-stage trial in China, ...